title: Edaravone suppresses degradation of type II collagen.
abstract: Osteoarthritis (OA) is a degenerative joint disease affecting millions of people. The degradation and loss of type II collagen induced by proinflammatory cytokines secreted by chondrocytes, such as factor-α (TNF-α) is an important pathological mechanism to the progression of OA. Edaravone is a potent free radical scavenger, which has been clinically used to treat the neuronal damage following acute ischemic stroke. However, whether Edaravone has a protective effect in articular cartilage hasn't been reported before. In this study, we investigated the chondrocyte protective effects of Edaravone on TNF-α induced degradation of type Ⅱ collagen. And our results indicated that TNF-α treatment resulted in degradation of type Ⅱ collagen, which can be ameliorated by treatment with Edaravone in a dose dependent manner. Notably, it was found that the inhibitory effects of Edaravone on TNF-α-induced reduction of type Ⅱ collagen were mediated by MMP-3 and MMP-13. Mechanistically, we found that Edaravone alleviated TNF-α induced activation of STAT1 and expression of IRF-1. These findings suggest a potential protective effect of Edaravone in OA.
authors.affiliation: Department of Orthopedic Surgery, Yan Tai Shan Hospital, China. Electronic address: huangchen456@tom.com.
authors.forename: Chen
authors.initials: C
authors.lastname: Huang
authors.affiliation: Department of Orthopedic Surgery, Yan Tai Shan Hospital, China.
authors.forename: Guangjun
authors.initials: G
authors.lastname: Liao
authors.affiliation: Department of Orthopedic Surgery, Yan Tai Shan Hospital, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Han
authors.affiliation: Department of Orthopedic Surgery, Yan Tai Shan Hospital, China.
authors.forename: Guofeng
authors.initials: G
authors.lastname: Zhang
authors.affiliation: Department of Orthopedic Surgery, Yan Tai Shan Hospital, China.
authors.forename: Benguo
authors.initials: B
authors.lastname: Zou
mesh_terms: D000983:Antipyrine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002478:Cells, Cultured; D019902:Chondrocytes / Q000187:drug effects*; D024043:Collagen Type II / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D000077553:Edaravone; D004789:Enzyme Activation / Q000187:drug effects; D016166:Free Radical Scavengers / Q000494:pharmacology; D006801:Humans; D053509:Matrix Metalloproteinase 13 / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D024043:Collagen Type II; D016166:Free Radical Scavengers; D014409:Tumor Necrosis Factor-alpha; D053509:Matrix Metalloproteinase 13; D000077553:Edaravone; D000983:Antipyrine
keywords: Collagen; Edaravone; IRF-1; MMP-13; Osteoarthritis (OA); Type Ⅱ